Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants (LVXSCID-ND)
Severe Combined Immunodeficiency Disease, X-linked
About this trial
This is an interventional treatment trial for Severe Combined Immunodeficiency Disease, X-linked focused on measuring SCID, SCID-X1, X-linked SCID, immunodeficiency, gene therapy
Eligibility Criteria
Inclusion Criteria:
* Treatment Eligibility Criteria:
- Age <2 years at the time of enrollment.
- No prior therapy with allogeneic stem cell transplantation.
- A clinical diagnosis of SCID-X1 documented in the medical record.
- A proven mutation in the common gamma chain gene as defined by direct sequencing of patient DNA.
- Age > 2 months to < 1 year of age at the time of busulfan administration.
- Less than 300 CD3+ T-cells by flow cytometry or higher if evidence of maternal engraftment as supported by peripheral blood FISH analysis for XY and XX.
- Lymphocyte proliferation to phytohemagglutinin (PHA) <10% of the lower limit of normal for the laboratory.
Treatment Exclusion Criteria:
- Availability of a HLA matched sibling for allogeneic transplantation
- Prior therapy with allogeneic stem cell transplantation
- Positive for HIV infection by genome PCR
- Presence of a medical condition indicating that survival will be less than 16 weeks such as the requirement for mechanical ventilation, severe failure of a major organ system, or evidence of a serious, progressive infection that is refractory to medical therapy.
- The presence of any medical contraindications to general anesthesia and bone marrow harvest by aspiration
- A social situation indicating that the family may not be able to comply with protocol procedures and recommended medical care.
Sites / Locations
- University of California-San Francisco
- St. Jude Children's Research Hospital
- Seattle Children's Research Institute
Arms of the Study
Arm 1
Experimental
Treatment
Participants will undergo a bone marrow harvest in the operating room to obtain bone marrow cells. Cells will be isolated and purified utilizing the CliniMacs device. These cells will undergo vector transduction with the lentiviral vector that contains a normal copy of the γc gene gene (CL20-i4-EF1α-hγc-OPT) and then the transduced cells will be reinfused back into the patient. Participants will receive a conditioning regimen of busulfan 3 days prior and 2 days prior to infusion of vector-corrected cells.intervention: CL20-i4-EF1α-hγc-OPT